Crestor vs Zetia: Cost, Access, and Clinical Outcomes Compared

How These Two Drugs Actually Work

Rosuvastatin inhibits HMG-CoA reductase in the liver, blocking the rate-limiting step of cholesterol synthesis. Ezetimibe targets NPC1L1 transporters at the brush border of the small intestine, reducing dietary and biliary cholesterol absorption by approximately 54% [1].

This mechanistic difference matters for cost and access decisions. Rosuvastatin achieves greater absolute LDL reduction as a single agent. At 40 mg, it lowers LDL-C by a mean of 55% from baseline, making it the most potent statin available per milligram [2]. Ezetimibe monotherapy reduces LDL-C by only 18 to 20%, but its value lies in combination therapy. The 2018 ACC/AHA Cholesterol Guidelines position ezetimibe as a first-line add-on for patients not reaching LDL targets on maximally tolerated statin therapy [3].

The two drugs are not interchangeable. They occupy different rungs on the treatment ladder. A patient switching from rosuvastatin to ezetimibe monotherapy would typically see LDL rise. A patient adding ezetimibe to rosuvastatin would see LDL fall an additional 21 to 25% beyond what the statin alone achieves.

Landmark Trial Evidence: JUPITER vs IMPROVE-IT

The strongest cardiovascular outcomes data for rosuvastatin comes from JUPITER (N=17,802), published in the New England Journal of Medicine in 2008. This trial enrolled adults with LDL-C below 130 mg/dL but high-sensitivity C-reactive protein (hsCRP) of 2.0 mg/L or higher. Rosuvastatin 20 mg daily reduced the primary composite endpoint of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death by 44% compared with placebo (HR 0.56 to 95% CI 0.46, 0.69, P<0.00001) [1].

For ezetimibe, IMPROVE-IT (N=18,144) remains the defining trial. Published in 2015, it randomized post-acute coronary syndrome patients to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. At a median follow-up of 6 years, the combination arm showed a 6.4% relative risk reduction in the primary composite MACE endpoint (32.7% vs 34.7%, HR 0.936 to 95% CI 0.89, 0.99, P=0.016) [4].

These trials answer different questions. JUPITER proved rosuvastatin prevents first cardiovascular events in an inflammatory-risk population. IMPROVE-IT proved ezetimibe, layered onto a statin, provides incremental benefit in secondary prevention. No large randomized trial has directly compared rosuvastatin monotherapy to ezetimibe monotherapy for hard cardiovascular outcomes.

Generic Pricing Breakdown

Both drugs lost patent exclusivity years ago. Crestor's patent expired in 2016; Zetia's expired in 2017. This shifted the cost conversation entirely.

Brand-name Crestor still carries a list price above $300 per month, but fewer than 3% of prescriptions fill at brand pricing. Generic rosuvastatin calcium tablets are manufactured by Teva, Mylan, Sandoz, Aurobindo, and others. GoodRx cash prices for rosuvastatin 20 mg (#30) range from $7.50 to $28 depending on pharmacy and region [5]. Costco and Mark Cuban's Cost Plus Drugs consistently price rosuvastatin 20 mg below $10 for a 30-day supply.

Generic ezetimibe 10 mg (#30) runs $9 to $44 at retail, with a median around $15 using discount cards. The price spread is wider because fewer manufacturers produce ezetimibe, and some pharmacy benefit managers (PBMs) negotiate different acquisition costs. Walmart's $4 generic list includes rosuvastatin 5 mg and 10 mg, but not ezetimibe, which creates a meaningful out-of-pocket gap for uninsured or underinsured patients.

The combination tablet Vytorin (simvastatin/ezetimibe) costs $25 to $60 as a generic, roughly equivalent to filling both components separately.

Insurance Formulary Positioning

On commercial insurance, both generic rosuvastatin and generic ezetimibe sit at Tier 1 or Tier 2, meaning copays between $0 and $15 for most plans. The practical difference is negligible for insured patients.

Medicare Part D formulary data from Q1 2026 shows rosuvastatin on 98% of surveyed plans at preferred generic tier. Ezetimibe appears on 96% of plans, also at preferred generic tier [6]. Prior authorization requirements are uncommon for either drug. Some plans require step therapy documentation showing statin intolerance before covering ezetimibe monotherapy, but this applies to fewer than 8% of commercial formularies.

For Medicaid patients, both generics are covered without prior authorization in all 50 states. State Medicaid preferred drug lists occasionally favor one generic manufacturer over another, but therapeutic access is not restricted.

Dr. Seth Martin, a preventive cardiologist at Johns Hopkins, noted in a 2023 ACC presentation: "Cost is rarely the barrier it once was for statins or ezetimibe. The access problem has shifted to PCSK9 inhibitors and bempedoic acid, not to these two generic workhorses."

Who Gets Rosuvastatin and Who Gets Ezetimibe

The 2018 ACC/AHA Guidelines and the 2022 ACC Expert Consensus Decision Pathway both position high-intensity statins (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) as first-line therapy for patients with clinical ASCVD, LDL-C of 190 mg/dL or higher, diabetes aged 40, 75, or 10-year ASCVD risk of 7.5% or higher [3].

Ezetimibe enters the algorithm at a specific decision node. If a patient on maximally tolerated statin therapy has not achieved a 50% LDL reduction (or LDL remains above 70 mg/dL in very high-risk ASCVD), ezetimibe 10 mg is recommended as the next addition before considering PCSK9 inhibitors [3].

There are three scenarios where ezetimibe might serve as primary therapy:

1. Complete statin intolerance confirmed by rechallenge (approximately 5 to 7% of patients)
2. Myopathy risk factors making any statin dose inappropriate (rhabdomyolysis history, certain drug interactions)
3. Patient refusal of statin therapy despite counseling

In these cases, ezetimibe monotherapy provides modest LDL reduction (18 to 20%) but lacks the strong outcomes data that rosuvastatin carries from JUPITER [1].

Combination Strategy: When You Use Both

The most common clinical scenario involves prescribing both drugs simultaneously. A patient on rosuvastatin 40 mg with LDL still above goal adds ezetimibe 10 mg and achieves an additional 21 to 25% LDL lowering. Combined monthly cost at generic cash pricing: $17 to $50 total.

IMPROVE-IT demonstrated that this "statin plus ezetimibe" strategy translates to fewer cardiovascular events over time [4]. The number needed to treat (NNT) over 7 years in IMPROVE-IT was 50. This figure improves for higher-risk subgroups: patients with diabetes in IMPROVE-IT showed a 5.5% absolute risk reduction (NNT = 18) [4].

The ACC/AHA guidelines explicitly endorse this combination before escalating to injectable PCSK9 inhibitors, which cost $400 to $600 per month even after manufacturer rebates. From a pure cost-effectiveness standpoint, adding generic ezetimibe ($15/month) before jumping to evolocumab or alirocumab is one of the highest-value interventions in preventive cardiology.

Side Effect Profiles and Tolerability Costs

Rosuvastatin, like all statins, carries a dose-dependent risk of myalgia (5 to 10% in observational data, though nocebo-controlled trials like SAMSON suggest 90% of reported muscle symptoms are not pharmacologically caused) [7]. At 40 mg, rosuvastatin also raises the risk of proteinuria slightly and is associated with a small increase in new-onset diabetes (OR 1.25 per the JUPITER diabetogenic signal) [1].

Ezetimibe's side effect profile is remarkably bland. The most common adverse events in clinical trials were upper respiratory infection and diarrhea at rates barely exceeding placebo. Muscle toxicity does not increase when ezetimibe is added to a statin [4]. This tolerability advantage is why ezetimibe remains the standard rescue agent for patients who cannot tolerate full-dose statin therapy.

From a cost perspective, statin-related myalgia drives specialist referrals, CK blood draws, dose adjustments, and drug switching. These hidden costs do not apply to ezetimibe. For health systems managing large populations, ezetimibe's tolerability reduces downstream utilization.

Access Barriers and Practical Considerations

Mail-order pharmacies typically offer the lowest per-unit cost for both drugs. Express Scripts, Optum Rx, and CVS Caremark 90-day generic programs price rosuvastatin at $8 to $15 for 90 tablets and ezetimibe at $12 to $25 for 90 tablets.

For patients without insurance, manufacturer patient assistance programs exist for brand Crestor and brand Zetia, but these are largely irrelevant given generic availability. The more practical resource is GoodRx, RxAssist, or NeedyMeds discount cards, which bring cash prices below $15/month for either drug at major retail chains.

International price comparisons show even lower costs. In India and other generic-dominant markets, rosuvastatin 10 mg costs the equivalent of $0.50 to $1.50 per month. Canadian pharmacy pricing for rosuvastatin sits at roughly CAD $8 to $12 for 30 tablets. These reference prices demonstrate that even U.S. generic pricing retains margin above global cost floors.

Switching Between Rosuvastatin and Ezetimibe

Switching from rosuvastatin to ezetimibe is not equivalent to switching between two statins. Because ezetimibe produces only 18 to 20% LDL reduction as monotherapy versus rosuvastatin's 45 to 55%, an unmanaged switch will typically result in a 25, 35 percentage point loss of LDL-lowering efficacy.

The 2022 ACC Expert Consensus pathway states that patients discontinued from statins due to intolerance should have LDL rechecked 4 to 6 weeks after starting ezetimibe monotherapy to determine if additional therapy (bempedoic acid, inclisiran, or a PCSK9 inhibitor) is needed to reach risk-appropriate targets [3].

A direct quote from the ACC/AHA 2018 Guideline document: "For patients with clinical ASCVD at very high risk, if maximally tolerated LDL-C lowering therapy does not reduce LDL-C by 50% or to <70 mg/dL, adding ezetimibe is reasonable (Class IIa, Level of Evidence B-R)" [3].

Head-to-Head Cost-Effectiveness Data

A 2020 cost-effectiveness analysis published in the Journal of the American Heart Association modeled the incremental cost-effectiveness ratio (ICER) of adding ezetimibe to statin therapy in post-ACS patients. At generic pricing, the ICER was $17,200 per quality-adjusted life year (QALY) gained, well below the $50,000/QALY willingness-to-pay threshold commonly used in U.S. health economics [8].

Rosuvastatin's cost-effectiveness as primary prevention was established in a post hoc JUPITER economic analysis showing $25,198 per QALY gained in hsCRP-elevated patients [9]. Both figures make these drugs among the most cost-effective interventions in cardiovascular medicine.

The contrast with newer agents is stark. PCSK9 inhibitors initially cost over $500,000 per QALY before price reductions brought them to roughly $80,000, $150,000 per QALY. Inclisiran's twice-yearly dosing costs approximately $6,500 per year. Against these alternatives, rosuvastatin at $10/month and ezetimibe at $15/month represent extraordinary value.

When to Choose One Over the Other

Select rosuvastatin as first-line when the patient has no statin intolerance, requires greater than 30% LDL reduction, and falls into a guideline-indicated statin-benefit group. The drug's broad outcomes evidence base, low cost, and once-daily dosing make it the default choice for most patients needing lipid-lowering therapy.

Select ezetimibe when the patient needs additional LDL lowering beyond maximally tolerated statin therapy, has confirmed statin intolerance and requires monotherapy, or when the combination of rosuvastatin plus ezetimibe offers the most cost-effective path to LDL goal before escalating to expensive injectables. At current generic pricing, prescribing both simultaneously adds $10 to $20 per month over statin monotherapy.